Effectiveness of focused ultrasound for high risk human papillomavirus infection-related cervical lesions

Figures & data

Figure 1. Flow diagram for patient selection.

Table 1. Distribution of HR-HPV subtypes in the study population.

HR-HPV subtype	Number of patients (%)	HR-HPV subtype	Number of patients (%)
16	93 (15.7)	52	176 (29.73)
18	48 (8.11)	56	45 (7.60)
31	28 (4.73)	58	107 (18.07)
33	32 (5.41)	59	24 (4.05)
35	27 (4.56)	66	35 (5.91)
39	69 (11.66)	68	35 (5.91)
45	13 (2.20)	82	8 (1.35)
51	56 (9.46)

Table 2. HR-HPV infection types in each group.

HR-HPV infection type	Type I	Type II	Type III	Type IV	χ^2 value	p Value
FU Group (n = 300)	58 (19.3%)	33 (11.0%)	172 (57.3%)	37 (12.3%)	19.747	0.000
Medication Group (n = 292)	27 (9.2%)	19 (6.5%)	190 (65.1%)	56 (19.2%)

Table 3. Study outcome time and median time for HR-HPV clearance in each group.

	Outcome time (month)			Median time for Clearance (month)
	Minimum	P50	Maximum	Median time (95% CI)	χ^2value	p Value
FU Group (n = 300)	1	6	32	6 (5.24, 6.76)	198.902	0.000
Medication Group(n = 292)	1	14	60	26 (22.32, 29.68)

Table 4. Accumulated clearance rate of HR-HPV infection in each group.

Time (month)	HR-HPV clearance cases (%)
	0-6M	6-12M	12-18M	18-24M	After 24M
FU group (n = 300)	142 (47.3%)	52 (64.7%)	12 (68.7%)	11 (72.3%)	7 (74.7%)
Medication group (n = 292)	17 (5.8%)	30 (16.1%)	31 (26.7%)	14 (31.5%)	28 (41.1%)
p Value	0.000	0.000	0.000	0.000	0.000

Table 5. Univariate and multivariate Cox regression analyses for analyzing variables associated with the HR-HPV clearance rate.

Variable	Univariate analysis		Multivariate analysis
	HR (95%CI)	p Value	HR (95%CI)	p Value
Age (≥30 vs < 30)	1.109 (0.749–1.388)	0.903	0.880 (0.646–1.200)	0.419
Treatment (FU vs medication)	4.854 (3.799–6.203)	0.000	4.927 (3.840–6.321)	0.000
Non-HPV16/18 infection vs HPV16/18 infection	1.141 (0.892–1.460)	0.295	0.915 (0.711–1.178)	0.491
Single HR-HPV infection vs multiple HR-HPV infection	1.613 (1.227–2.121)	0.001	1.534 (1.163–2.023)	0.002

Figure 2. HR-HPV clearance rate according to treatment method.

Figure 3. HR-HPV clearance rate by pathological type in the FU group.

Figure 4. HR-HPV clearance rate by preoperative HR-HPV infection status in the FU group.